Biomedical Research Institute (ABRI) is the discovery and preclinical research
organization of the International network for the Advancement of Viable
Applicable Innovations in Life sciences (InAVAIL). InAVAIL consists of
R&D-performing organizations, R&D consulting enterprises and service providers working to common aims. This network
was established by our scientific leader, Dr. Sabrina Mattoli, to accelerate the development of market-creating innovations
by facilitating the sharing of innovative methodologies, data, infrastructures and resources within an international, multidisciplinary
and intersectoral consortium.
ABRI is specifically devoted to the advancement
of basic and translational research in chronic inflammatory and fibrotic pulmonary diseases of uncertain etiology or complex
Our research programs are addressed to discover new therapeutic
targets for the development of drugs more effective than those currently available, to identify the most appropriate biomarkers
of therapeutic responsiveness for treatment personalization, and to test the therapeutic potential of novel stem cell-based
We have various operative units in Europe, with state-of-the-art
laboratories in Munich (Germany) and Warsaw (Poland). The Discovery and Translational Research Center in Munich and the Stem
Cell Research Center in Warsaw have GMP/GLP-compliant facilities. These centers also operate as contract research units to
provide logistic and highly-qualified scientific and technical support for the conduction of basic research investigations
and preclinical studies in the fields of pulmonary medicine and cell-based therapies for pulmonary disorders.
Copyright © 1998-2019, Avail Biomedical Research Institute. All rights reserved.